Meeting
2019 Genitourinary Cancers Symposium
Pembrolizumab in men with heavily treated metastatic castration-resistant prostate cancer (mCRPC).
Authors
Matthew D Tucker
Duke University Medical Center, Durham, NC
Matthew D Tucker , Jason Zhu , William R. Berry , Sundhar Ramalingam , Tian Zhang , Michael Roger Harrison , Yuan Wu , Patrick Healy , Daniel J. George , Andrew J. Armstrong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 172)
DOI
10.1200/JCO.2019.37.7_suppl.172
Abstract #
172
Poster Bd #
G15
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone acetate (abi) or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B efficacy, safety and, biomarker results.
First Author: Srikala S. Sridhar
Poster
2017 ASCO Annual Meeting
Phase 1b/2 keynote-365 trial: Pembrolizumab (pembro) combination therapy in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Evan Y. Yu
Poster
2017 Genitourinary Cancers Symposium
A phase II study of the anti-programmed death ligand-1 antibody durvalumab (D; MEDI4736) in combination with PARP inhibitor, olaparib (O), in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Fatima Karzai
Poster
2024 ASCO Genitourinary Cancers Symposium
The survival outcomes for men with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination deficiencies (HRD) treated with radium-223: Princess Margaret Cancer Centre (PMCC) experience.
First Author: Esmail M. Al-Ezzi